Docetaxel Followed by Doxorubicin Plus Cyclophosphamide for Node Positive or High-Risk Primary Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Docetaxel|DRUG: Doxorubicin|DRUG: Cyclophosphamide
Sponsor: SCRI Development Innovations, LLC
Collaborators: Aventis Pharmaceuticals